Logo

American Heart Association

  16
  0


Final ID:

Aldosterone synthase inhibitors – a potentially new class of antihypertensive drugs

  • Laffin, Luke  ( Cleveland Clinic Foundation , Cleveland , Ohio , United States )
  • Luther, James  ( VANDERBILT UNIV MED CTR , Nashville , Tennessee , United States )
  • Kline, Gregory  ( University of Calgary , Calgary , Alberta , Canada )
  • Author Disclosures:
    Luke Laffin: DO have relevant financial relationships ; Research Funding (PI or named investigator):Mineralys:Active (exists now) ; Consultant:Ripple Medical:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Recor:Active (exists now) ; Royalties/Patent Beneficiary:Elsevier:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:Crispr Theapeutics:Active (exists now) ; Research Funding (PI or named investigator):Kardigan:Active (exists now) ; Consultant:Astrazeneca:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now) | James Luther: DO have relevant financial relationships ; Consultant:Mineralys:Active (exists now) ; Other (please indicate in the box next to the company name):AHA (editorial board):Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) | Gregory Kline: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts on this topic:
Aldosterone and mineralocorticoid receptors beyond the kidney

Jaffe Iris, Harrison David, Jaisser Frederic

The wide spectrum of primary aldosteronism

Vaidya Anand, Hundemer Gregory, Adler Gail

You have to be authorized to contact abstract author. Please, Login
Not Available